For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Teva Pharmaceutical Industries Ltd. (TEVA) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Teva Pharmaceutical Industries Ltd. is a member of our Medical group, which includes 925 different companies and currently sits at #8 in the Zacks Sector Rank ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows: UBS European Healthcare Conference Tuesday, March 3, 2026 (investor meetings only – no webcast)Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026, at 10:00 am ET (webcast fireside chat)Barclays 28th Annual Global Healthcare Co ...

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treatment option and further building on its differentiated LAI franchise and scientific leadership in complex neurological c ...

Investors might want to bet on Teva Pharmaceutical Industries Ltd. (TEVA) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.T ...

Core Insights - The biotech industry experienced significant developments this week, including FDA approvals, clinical trial results, and licensing agreements, indicating a dynamic landscape for investment opportunities and advancements in healthcare [1]. FDA Approvals & Rejections - NRx Pharmaceuticals is on track for FDA approval of NRX-100, with existing clinical data and real-world evidence from over 65,000 patients potentially supporting a New Drug Application (NDA) under Fast Track Designation [2][3]. - Kane Biotech received FDA clearance for its Revyve Antimicrobial Skin and Wound Cleanser, which targets wound bacteria and biofilms, with plans for manufacturing scale-up in 2026 [4][5]. - Johnson & Johnson's RYBREVANT FASPRO received FDA approval for a simplified monthly dosing schedule, enhancing treatment options for patients with advanced non-small cell lung cancer [6][7]. - Spruce Biosciences reported positive feedback from FDA Type B meetings for its enzyme replacement therapy for Sanfilippo syndrome type B, with a targeted BLA filing in Q4 2026 [8][9]. - Moderna's seasonal influenza vaccine submission (mRNA-1010) is under FDA review, with a PDUFA date set for August 5, 2026, aiming for availability in the 2026/2027 flu season [10][11]. - Disc Medicine received a Complete Response Letter (CRL) for its NDA for Biopertin in erythropoietic protoporphyria, citing insufficient correlation with sunlight exposure endpoints [13][14]. - AbbVie and Genentech's combination regimen of VENCLEXTA and Acalabrutinib for chronic lymphocytic leukemia (CLL) received FDA approval, showing a 35% reduction in disease progression risk compared to standard treatment [15][16]. Deals - Theriva Biologics entered an exclusive licensing agreement with Rasayana Therapeutics for SYN-020, receiving a $3 million upfront payment and potential milestone payments totaling up to $38 million [17][18]. - Sensei Biotherapeutics acquired Faeth Therapeutics, expanding its oncology portfolio with the investigational asset PIKTOR, and announced a concurrent private placement of $200 million to advance clinical milestones [19][20]. Clinical Trials - Breakthroughs - Eli Lilly's Taltz and Zepbound combination therapy showed positive results in a Phase 3 trial for plaque psoriasis and obesity, achieving superior outcomes compared to Taltz alone [21][22]. - Zealand Pharma reported positive Phase 1a results for ZP9830, a Kv1.3 channel blocker, demonstrating safety and tolerability in healthy volunteers [23][24]. - Novartis' Remibrutinib met primary endpoints in a Phase 3 trial for chronic inducible urticaria, showing significant response rates compared to placebo [26][27]. - Ocular Therapeutix's AXPAXLI demonstrated superiority over aflibercept in a Phase 3 trial for wet age-related macular degeneration, although stock prices fell due to investor disappointment [28][29]. - Rallybio's RLYB116 Phase 1 study showed promising results for immune platelet transfusion refractoriness, with plans for a Phase 2 trial in 2026 [31][32]. - Teva and Sanofi's Duvakitug Phase 2b trial demonstrated durable efficacy in ulcerative colitis and Crohn's disease, reinforcing the rationale for ongoing Phase 3 programs [35][36]. - Genentech's Gazyva met primary endpoints in a Phase III study for primary membranous nephropathy, showing significant remission rates compared to tacrolimus [38][39].

Teva Pharmaceutical Industries Limited (NYSE:TEVA) ranks among billionaire Stanley Druckenmiller’s 10 best stock picks. Truist Securities boosted Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s price target to $38 from $36 on January 28, retaining a Buy rating for the pharma company. The revision comes after Teva’s Q4 2025 results that featured a one-time $500 million Duvakitug Phase 3 landmark contribution. Truist emphasized that the upcoming enactment of the Inflation Reduction Act and recent inve ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, representing a substantial shift in the global economy driven by AI innovation [2] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is believed to be redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4] - Prominent investors, including Bill Gates and Warren Buffett, recognize AI as a significant technological advancement, with potential benefits across various sectors such as healthcare and education [8]

Market Performance - The Tel Aviv Stock Exchange experienced a rise, with the Tel Aviv 35 Index increasing by 0.87% to a new record of 4,232.65 points [1] - The Tel Aviv 125 Index also reached a new record, rising by 0.83% to 4,202.51 points [1] - The BlueTech Global Index rose by 1.19% to 676.98 points [1] - The All Bond corporate bond index fell by 0.10% to 424.55 points [1] - Total turnover in equities was NIS 4.84 billion, while bond turnover was NIS 6.39 billion [1] Currency Exchange Rates - The shekel-dollar exchange rate was set 0.225% lower at NIS 3.098/$ [2] - The shekel-euro exchange rate decreased by 0.093% to NIS 3.668/€ [2] Notable Stock Movements - Enlight Renewable Energy led the market with a rise of 3.45% on the highest trading turnover [3] - Elbit Systems Ltd. saw a significant increase of 4.33%, marking the largest rise on the Tel Aviv 35 Index [3] - Other notable gainers included OPC Energy (up 4.19%), Strauss Group (up 2.74%), Tower Semiconductor Ltd. (up 3.99%), and Camtek (up 4.06%) [3] Declining Stocks - Azrieli Group experienced the largest decline on the Tel Aviv 35 Index, falling by 4.03% [4] - Nice saw a decrease of 1.95%, while Teva Pharmaceutical Industries Ltd. fell by 0.93% [4] - ICL reported a decline of 3.93% following its fourth quarter results [4]

​Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the Best Performing Foreign Stocks to Buy Now. Wall Street is bullish on Teva Pharmaceutical since its fiscal Q4 2025 earnings were released on January 28. ​Recently, on February 10, Goldman Sachs analyst Matthew Dellatorre reiterated a Buy rating on the stock and raised the price target from $36 to $45. Earlier on January 28, Trust Financial also raised its price target from $36 to $38, while maintaining a Buy rating on the stock. ​Teva Phar ...

Core Insights - The conference call is focused on the Duvakitug IBD Ph2b Maintenance Topline Results, indicating a significant development in the company's clinical research efforts [1]. Group 1 - The call is coordinated by Alex, with Chris Stevo serving as the Senior Vice President of Investor Relations, highlighting the company's commitment to transparent communication with stakeholders [2]. - Chris Stevo emphasizes the forward-looking statements made during the call, indicating the company's strategic outlook and future plans [2]. - The company has no obligation to update forward-looking statements, which may suggest a cautious approach to investor communications [2].